Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial

Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action. Combining Medications to Enhance Depression Outcomes...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 2018-07, Vol.234, p.34-37
Main Authors: Jha, Manish K., Wakhlu, Shereen, Dronamraju, Neha, Minhajuddin, Abu, Greer, Tracy L., Trivedi, Madhukar H.
Format: Article
Language:English
Subjects:
Adult
Antidepressant medications
Antidepressive Agents, Second-Generation - therapeutic use
Antidepressive Agents, Tricyclic - therapeutic use
Biomarkers
Body Mass Index
Bupropion - therapeutic use
Citalopram - therapeutic use
Depression - drug therapy
Depressive Disorder, Major - drug therapy
Drug Combinations
Drug Therapy, Combination
Female
Humans
Major depressive disorder
Male
Mianserin - analogs & derivatives
Mianserin - therapeutic use
Middle Aged
Mirtazapine
Moderator
Obesity
Overweight - complications
Patient Selection
Treatment Outcome
Treatment selection
Venlafaxine Hydrochloride - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action. Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n = 662) were categorized as normal- or underweight (
ISSN:0165-0327
1573-2517
1573-2517
DOI:10.1016/j.jad.2018.02.089